DEA Revokes Bronx MD's License for Law-Breaking Prescriptions
Published Date: 4/16/2025
Notice
Summary
Dr. David Israel from Bronx, NY, lost his DEA license because he wrote prescriptions for controlled drugs in ways that broke the law. This means he can’t legally handle these drugs anymore, and his registration expired in late 2023. If you’re a patient or pharmacy, this change is immediate and affects how controlled substances are managed.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
DEA Revokes Dr. David Israel's Registration
The Drug Enforcement Administration revoked David Israel, M.D.'s DEA Certificate of Registration No. BI8368828 and denied any pending applications to renew, modify, or add a registration in New York. The Agency notes his DEA registration had expired on November 30, 2023, and the revocation order is effective May 16, 2025.
Findings: Unlawful Prescriptions and Credential Sharing
The Agency found that from at least April 2, 2020 through June 11, 2023, Dr. Israel issued numerous controlled-substance prescriptions outside the usual course of professional practice and for other than a legitimate medical purpose. The record includes admissions that he provided secure log-in credentials to an individual (T.C.) who self-issued prescriptions for lorazepam and diazepam (Schedule IV) and dextroamphetamine-amphetamine (Schedule II), and that he fraudulently issued multiple oxycodone 30 mg (Schedule II) prescriptions, including five in C.G.'s name.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Previous / Next Documents
Previous: 2025-06423 — Market Dominant Price Adjustment
The Postal Service is planning to raise prices on some mail and shipping services because of inflation. This affects anyone who sends letters or packages, both inside the U.S. and internationally. The public can share their thoughts before the changes happen, so keep an eye out for deadlines and new rates soon!
Next: 2025-06425 — Empire Pharmacy Inc.; Skyline Pharmacy Inc.; Decision and Order
Empire Pharmacy and Skyline Pharmacy in Philadelphia lost their DEA registrations because they didn’t keep proper records of controlled substances, which could risk public safety. Their registrations were suspended immediately, and since they didn’t ask for a hearing, the suspension and revocation are now final. This means they can’t legally handle controlled drugs anymore, affecting their business and customers starting now.